Drug
S095035
S095035: highest development phase Phase 1/2, developed by Servier. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| S095035 NCT06188702 | Phase 1/2 | MTAP-deleted Solid Tumors |
Latest
No recent events.
Follow S095035 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.